methyl (2E)-3-(6-bromopyridin-3-yl)prop-2-enoate | 918305-51-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl (2E)-3-(6-bromopyridin-3-yl)prop-2-enoate
• 英文别名: (E)-methyl 3-(6-bromopyridin-3-yl)acrylate；(E)-3-(6-bromo-pyridin-3-yl)-acrylic acid methyl ester；(E)-3-(6-bromopyridin-3-yl)acrylic acid methyl ester；3-(6-Bromo-pyridin-3-yl)-acrylic acid methyl ester；3-(6-bromopyridin-3-yl)acrylic acid methyl ester；Methyl (2E)-3-(6-bromopyridin-3-YL)prop-2-enoate；methyl (E)-3-(6-bromopyridin-3-yl)prop-2-enoate
• CAS: 918305-51-8
• 化学式: C₉H₈BrNO₂
• 分子量: 242.072
• InChiKey: YURUVQCOYDKFPM-HWKANZROSA-N

物化性质

• 沸点：
  332.3±27.0 °C(Predicted)
• 密度：
  1.514±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl (2E)-3-(6-bromopyridin-3-yl)prop-2-enoate 在 sodium hydroxide 、 水 、 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 3-(6-bromopyridin-3-yl)acrylic acid
  参考文献：
  名称：

  Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase

  摘要：

  本发明涉及式I的杂环丙烯酰胺， 其中Het、X、Ra、Rb、R1、R2和R3具有权利要求中所示的含义，这些化合物调节内皮型一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体地，式I的化合物上调内皮型一氧化氮合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及制备式I化合物的方法，包括它们的药物组合物，以及利用式I化合物制造用于刺激内皮型一氧化氮合酶表达或治疗各种疾病的药物，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏功能不全等。

  公开号：

  EP1939180A1
• 作为产物：
  描述：

  甲氧羰基亚甲基三苯基正膦 、 2-溴-5-醛基吡啶 在 甲醇 、 silica gel 、 ethyl acetate heptane 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 methyl (2E)-3-(6-bromopyridin-3-yl)prop-2-enoate
  参考文献：
  名称：

  Heteroaryl-Substituted Amides Comprising An Unsaturated Or Cyclic Linker Group, And Their Use As Pharmaceuticals

  摘要：

  本发明涉及以下公式I的N-烷基酰胺，其中A、Het、X、R1、R2和R3具有声明中指出的含义，这些化合物调节内皮型一氧化氮(NO)合酶的转录，并是有价值的药理活性化合物。具体而言，公式I的化合物上调内皮型NO合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或规范降低的NO水平的情况。本发明还涉及制备公式I化合物的方法，包括它们的制药组合物，以及使用公式I化合物制造用于刺激内皮型NO合酶表达或用于治疗各种疾病，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏衰竭等的药物的用途。

  公开号：

  US20080167342A1

文献信息

• Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1741708A1

  公开（公告）日：2007-01-10

  The present invention relates to N-alkylamides of the formula I, in which A, Het, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及公式I的N-烷基酰胺， 其中A、Het、X、R1、R2和R3具有权利要求中所指示的含义，这些化合物调节内皮型一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体地，公式I的化合物上调内皮型一氧化氮合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及制备公式I化合物的方法，包括它们的药物组合物，以及利用公式I化合物制造用于刺激内皮型一氧化氮合酶表达或治疗各种疾病的药物，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏功能不全等。
• Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
  申请人：Amorepacific Corporation

  公开号：EP1882687A1

  公开（公告）日：2008-01-30

  This present invention relates to novel compounds, of the formula (I), isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1;VR1;TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, inflammatory disease of the joints, neuropathies, HIV-related neuropathy, nerve injury, neurodegeneration, stroke, urinary bladder hypersensitivity including urinary incontinence, cystitis, stomach duodenal ulcer, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), fecal urgency, gastro-esophageal reflux disease (GERD), Crohn's disease, asthma, chronic obstructive pulmonary disease, cough, neurotic/allergic/inflammatory skin disease, psoriasis, pruritus, prurigo, irritation of skin, eye or mucous membrane, hyperacusis, tinnitus, vestibular hypersensitivity, episodic vertigo, cardiac diseases such as myocardial ischemia, hair growth-related disorders such as effluvium, alopecia, rhinitis and pancreatitis.

  这项发明涉及新化合物，其化学式为(I)，其异构体或其药学上可接受的盐作为辣椒素受体（辣椒素受体1; VR1; TRPV1）拮抗剂；以及含有该化合物的药物组合物。本发明提供了一种用于预防或治疗疾病的药物组合物，如疼痛、关节炎炎症性疾病、神经病、艾滋病相关神经病、神经损伤、神经退行性疾病、中风、包括尿失禁、膀胱过敏、膀胱炎、胃十二指肠溃疡、肠易激综合征（IBS）和炎症性肠病（IBD）、粪便紧急情况、胃食管反流病（GERD）、克罗恩病、哮喘、慢性阻塞性肺病、咳嗽、神经症/过敏/炎症性皮肤病、牛皮癣、瘙痒症、疹痒症、皮肤、眼睛或粘膜刺激、听觉过敏、耳鸣、前庭过敏、阵发性眩晕、心脏疾病如心肌缺血、与头发生长有关的疾病如脱发、脱发、鼻炎和胰腺炎。
• [EN] NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT<br/>[FR] NOUVEAUX COMPOSÉS ACTIVATEURS DE GLUCOKINASE, COMPOSITIONS CONTENANT DE TELS COMPOSÉS, ET MÉTHODES DE TRAITEMENT
  申请人：MERCK SHARP & DOHME

  公开号：WO2014099578A1

  公开（公告）日：2014-06-26

  Novel pyridine-2-carboxamide derivatives of formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are effective as glucokinase activating agents. Pharmaceutical compositions and methods of treatment are also included.

  公开了式I的新型吡啶-2-羧酰胺衍生物及其药用盐，用于治疗或预防2型糖尿病和类似疾病。这些化合物作为葡萄糖激酶激活剂具有有效性。同时还包括药物组合物和治疗方法。
• HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS
  申请人：STROBEL Hartmut

  公开号：US20100016272A1

  公开（公告）日：2010-01-21

  The present invention relates to heteroarylacrylamides of the formula I, in which Het, X, R a , R b , R 1 , R 2 and R 3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及式I的杂环基丙烯酰胺，其中Het、X、Ra、Rb、R1、R2和R3具有声明中指示的含义，这些化合物调节内皮型一氧化氮（NO）合成酶的转录，是有价值的药理活性化合物。具体来说，式I的化合物上调内皮型NO合成酶的表达，可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及制备式I的化合物的过程，包括它们的制药组合物，以及使用式I的化合物制造用于刺激内皮型NO合成酶表达或治疗各种疾病的药物，包括心血管疾病，如动脉粥样硬化，血栓形成，冠状动脉疾病，高血压和心脏功能不全等。
• Heteroaryl-Substituted Amides Comprising An Unsaturated Or Cyclic Linker Group, And Their Use As Pharmaceuticals
  申请人：STROBEL Harmut

  公开号：US20080167342A1

  公开（公告）日：2008-07-10

  The present invention relates to N-alkylamides of the formula I, in which A, Het, X, R 1 , R 2 and R 3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及以下公式I的N-烷基酰胺，其中A、Het、X、R1、R2和R3具有声明中指出的含义，这些化合物调节内皮型一氧化氮(NO)合酶的转录，并是有价值的药理活性化合物。具体而言，公式I的化合物上调内皮型NO合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或规范降低的NO水平的情况。本发明还涉及制备公式I化合物的方法，包括它们的制药组合物，以及使用公式I化合物制造用于刺激内皮型NO合酶表达或用于治疗各种疾病，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏衰竭等的药物的用途。